Venus Remedies Limited uses cookies to improve site functionality, provide you with a better browsing experience, and to enable our partners to advertise to you. Detailed information on the use of cookies on this Site, and how you can decline them, is provided in our Privacy Policy. By using this Site or clicking on "OK", you consent to the use of cookies.
venus pharmaceutical
  • Research
    • AMR
    • Research Process
    • Pharmacovigilance
    • Visit VMRC
    • Events
  • About Us
    About Us Overview
    • Our Strategy
    • History
    • Operations
    • Board of Directors
    • Executive Team
    • Accreditation
    • Awards
    • Ethics & Compliance
    • IT Infrastructure
    • Global Presence
    • Responsibility
    • Contact Us
    FEATURED
    • Mrs. Ekta S. Chaudhary to Lead Venus Foundation

      We are immensely honored and delighted to announce the appointment of Mrs. Ekta S. Chaudhary as the new Chairperson of Venus Foundation. We are certain that this significant milestone will mark a new era of growth, inclusivity, and impactful change under her visionary leadership. Her presence adds not only strength to our initiatives but also to our soul.

    • Venus Remedies x Infex to Combat Antimicrobial Resistance in India

      Congratulations, Venusians. We have yet again marked another day on the calendar with gold! Venus Remedies Ltd. is delighted to announce a significant partnership with UK-based anti-infective drug development company, Infex Therapeutics. The alliance aims to tackle drug-resistant Gram-negative bacterial infections via MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.

    • Unlocking a New Milestone: US FDA Grants QIDP Status to VRP-034!

      We are proud to share a landmark achievement at Venus Remedies Limitedâ??our innovative formulation VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the U.S. FDA under the GAIN (Generating Antibiotics Incentives Now) Act. This recognition highlights Indiaâ??s vital role in combating antimicrobial resistance (AMR) and validates our years of dedicated research in critical care safety.

  • Media
    • Print Media
    • Press Release
    • Magazine
  • Career
    • Life at Venus
    • Internship at Venus
    • Find a Job
  • Our Presence
    • IB Presence
    • Global Presence
    • CPHI
    • Collaboration
    • Venus Pharma GmbH (VPG)
  • Products
    • Research-Based
    • Generic
    • Digital Payment
  • Newsletter

Venus Remedies Limited

{{title.title}}

{{sidemenu1.title}}
{{title2.subtitle}}
© 2023 Venus Remedies Limited